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Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but evidence suggests
a link between ICS usage and increased rates of respiratory infections. We assessed the
composition of the asthmatic airways microbiome in asthma patients taking low and high
dose ICS and the stability of the microbiome over a 2 week period.
Methods
We prospectively recruited 55 individuals with asthma. Of these, 22 were on low-dose ICS
and 33 on high-dose ICS (16 on budesonide, 17 on fluticasone propionate). Sputum from
each subject underwent DNA extraction, amplification and 16S rRNA gene sequencing of
the bacterial component of the microbiome. 19 subjects returned for further sputum induc-
tion after 24 h and 2 weeks.
Results
A total of 5,615,037 sequencing reads revealed 167 bacterial taxa in the asthmatic airway
samples, with the most abundant being Streptococcus spp. No significant differences in
sputum bacterial load or overall community composition were seen between the low- and
high-dose ICS groups. However, Streptococcus spp. showed significantly higher relative
abundance in subjects taking low-dose ICS (p = 0.002). Haemophilus parainfluenzae was
significantly more abundant in subjects on high-dose fluticasone propionate than those on
high-dose budesonide (p = 0.047). There were no statistically significant changes in micro-
biota composition over a 2-week period.
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Discussion
Whilst no significant differences were observed between the low- and high-dose ICS
groups, increased abundance of the potential pathogen H. parainfluenzae was observed in
patients taking high-dose fluticasone propionate compared to those taking high-dose bude-
sonide. The microbiota were stable over fourteen days, providing novel evidence of the




Asthma is a common cause of morbidity and mortality affecting an estimated 334 million indi-
viduals worldwide [1, 2]. In the UK, a stepwise approach to patient management recognises
five different stages reflecting severity and corresponding treatment strategies. All stages now
include inhaled corticosteroids (ICS) [3–5] which are also commonly prescribed in chronic
obstructive pulmonary disease (COPD) [6]. Although generally regarded as safe, considerable
evidence suggests their use is associated with an increased risk of respiratory infection in
COPD [6], and there are suggestions this may also be the case in asthma [4, 5] although not all
studies are in agreement [7].
The role of bacteria in the pathophysiology of asthma is not fully established or well-defined
[8, 9]. Fundamentally however, the key initial step towards a better understanding is character-
ising the abundance and diversity of bacteria in the asthmatic airways. This is now possible
due to techniques that characterise microbiome composition. Previous studies have described
bacterial species in the lower respiratory tract of individuals with asthma as well as making ten-
tative associations with disease severity [10, 11]. In compositional terms, the most common
genera across many microbiome studies of the asthmatic airways are Prevotella, Veillonella,
Haemophilus, Streptococcus and Moraxella [12–15]. Some of these genera contain potential
pathogens which are common causes of pneumonia, such as Haemophilus and Streptococcus
spp. and both of these species have been detected at higher frequencies in poorly controlled
asthmatics and subjects with treatment-resistant severe asthma [12, 14–16].
Here, we report the culture-independent analysis of bacteria present in sputum samples of
55 adults with asthma. Data were collected on the composition of the bacteria forming the
microbiome and the total bacterial and taxa-specific loads in the samples were quantified. Our
aims were to assess whether long-term use of different doses and types of ICS were associated




Fifty-five adults (age�18) were recruited from Nottingham City Hospital outpatient respira-
tory clinics or from an existing research subject database. All subjects provided written,
informed consent to the study which was approved by the National Research Ethics Commit-
tee East Midlands–Derby 1 (Ref 14/EM/0091).
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ANOVA, Analysis of Variance; BDP,
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LAMAs, Long-Acting Muscarinic Antagonists;
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Operational Taxonomic Units; qPCR, Quantitative
Polymerase Chain Reaction.
The study included adult patients who had not smoked for�10 years and had a<10 pack
year smoking history. All participants had a previous physician diagnosis of asthma (see S1
File) with no other respiratory diagnosis and no respiratory infection or antibiotic administra-
tion in the month prior to the study. Subjects with a post-bronchodilator FEV1 of<60% were
excluded for safety reasons due to the use of nebulised hypertonic saline. Recruitment targeted
20 patients on low-dose ICS (beclomethasone dipropionate (BDP)�400 μg/day, fluticasone
propionate (FP)�200 μg/day or budesonide (BUD)�400 μg/day for at least a year) and 30
taking high-dose ICS (FP�500 μg/day or BUD�800 μg/day for at least a year) with approxi-
mately equal numbers taking FP and BUD with or without long-acting β2-agonist.
Clinical measurements
At visit 1 demographic details and medical history were recorded. Spirometry was performed
and the Asthma Control [17] and Leicester Cough Questionnaires [18] administered. Exhaled
nitric oxide (FENO) measurement was performed prior to sputum induction. A subgroup of 20
patients agreeable to further visits were asked to return for repeat sputum induction after 24 h
and 2 weeks (see S1 File). This subgroup of patients were asked about changes in symptoms or
signs of active infection prior to each sputum induction and FEV1 prior to sputum induction
was assessed on each occasion.
Sample collection
Induced sputum samples were obtained from patients using 3, 4 & 5% hypertonic saline as pre-
viously described [19, 20]. Samples were frozen at -80˚C pending microbiological analysis.
Culture-independent analyses
DNA extraction. Sputum samples were disrupted as previously described [21]. Processing
followed recommendations for Gram-positive bacterial DNA extraction (GenElute™ Bacterial
Genomic DNA Kit) (see S1 File).
16S rRNA gene sequencing. 16S rRNA gene sequencing (V3-V4 region) was performed
on the Illumina MiSeq platform. Library preparation was carried out according to Illumina 16S
Metagenomic sequencing library preparation manual (see S1 File). The paired end reads were
rarefied to 9311 reads and transformed into Operational Taxonomic Units (OTU). This was
determined using the QIIME version 1.9.1 pipeline to cluster the 16S rRNA gene sequences.
qPCR. Total bacterial load qPCR was applied as previously described [22]. Two species-
specific qPCR assays were used to quantify the load of Haemophilus influenzae [23] and Strep-
tococcus pneumoniae [24] cells (see S1 File).
Statistical analyses
Microbiota analysis. To identify multiple interactive effects, normalised OTU relative
abundance (%) were multiplied by their corresponding qPCR-derived total bacterial load
obtained from the qPCR data to give a CFU/ml value. Diversity indices were calculated from
bootstrapped OTU tables using the vegan package of R (https://cran.r-project.org/web/
packages/vegan/vegan.pdf) such as richness, Shannon’s and Simpson’s. Prior to analyses, data
were assessed for homogeneity of variance and the normal distribution of the residuals. Non-
metric multidimensional scaling (NMDS) using Bray-Curtis distances assessed overall composi-
tional dissimilarity. Analysis of Similarity (ANOSIM) was used to identify differences between
the groups. The effect of treatment on individual OTU abundance was analysed using non-
parametric Wilcoxon rank sum tests with Bonferroni corrections for multiple comparisons.
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Quantitative bacterial load analysis. Quantitative PCR data (CFU/ml) were logarithm
(base = 10) transformed prior to analysis (SPSS Statistics v23.0; IBM Inc., USA). Same-day
data were analysed based on a non-pairwise comparison (independent T-test or Mann-Whit-
ney test). Data from different timepoints were compared using repeated measures ANOVA.
Results
Subjects
Induced sputum samples were collected from 55 subjects with asthma (Table 1). Twenty-two
and 33 subjects were treated with low- and high-dose ICS, respectively (Tables 1 and 2). In the
low-dose group, 10 subjects were taking BDP, 7 BUD and 5 FP; whereas in the high-dose
group, 16 subjects were taking BUD and 17 subjects FP (Table 2). None of the subjects were
taking LAMAs and 9 in the low-dose group and 30 in the high-dose group took concomitant
LABAs. Repeat sputum samples (after 24 h and 2 weeks) were collected from 19 subjects, 8 of
whom were taking low-dose ICS and 11 high-dose ICS (Table 2). None of the 19 subjects
Table 1. Study participant characteristics.
Low-dose ICS High-dose ICS
Frequency (%) Frequency (%) p-value
Total number included for analysis 22 (9 BDP / 7 BUD / 6 FLU) 33 (16 BUD / 17 FLU)
Mean age (range) 58.9 (14.4) (21–72) 54.1 (14.3) (25–80) 0.22
Sex: male 12 (54.6) 14 (41.2) 0.33
Ethnic group:
Black/Black British 0 2 (6.1)
White/White British 22 (100) 31 (93.9) 0.70
Smoking history:
Ex-smokers 7 (31.8) 11 (32.4)
Non smokers 15 (68.2) 22 (67.7) 0.97
Current eczema 4 (18.2) 3 (9.1) 0.42
Current hay fever 10 (45.5) 13 (39.4) 0.59
�1 severe asthma exacerbation in last year 0 (0) 4 (12) 0.28
Inhaled treatment
ICS only 13 (59.1) 3 (9.1)
ICS + LABA 9 (40.9) 30 (90.9)
Mean (SD) Mean (SD) p-value
ICS dose (BDP equivalent μg)� 400 (200)� 1000 (200)�
ACQ score 0.9 (0.6) 1.2 (0.8) 0.12
LCQ score� 19.0 (2.0)� 17.8 (3.5)� 0.08
FEV1% predicted 93.5 (28.0) 93.1 (22.5) 0.95
FEV1/FVC ratio % 68.8 (10.1) 71.2 (11.4) 0.43
Blood eosinophil count (x109 /L)� (peak in last 12 months) 0.2 (0.2) 0.3 (0.325) 0.41
FENO concentration (ppb)† 17.2 (12.8–23.1) † 13.0 (9.0–18.6) † 0.27‡
Sputum bacterial load (cfu/mL)� 1.35x107 (9.89x107) 8.86x106 (2.81x107) 0.27
�Figures shown are median and IQR
†Figures shown are geometric mean and 95% CI
‡ T-test comparing log FENO
ICS: inhaled corticosteroids, LABA: long-acting β2-agonist, BDP: beclomethasone dipropionate, BUD: budesonide, FLU: fluticasone propionate, ACQ: Asthma Control
Questionnaire, LCQ: Leicester Cough Questionnaire, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, FENO: exhaled nitric oxide.
https://doi.org/10.1371/journal.pone.0244681.t001
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reported any change in symptoms prior to repeat sputum induction at visits 2 and 3 and all
FEV1 measurements at visits 2 and 3 were within 150ml of the baseline values.
16S rRNA gene sequencing. A total of 5,615,037 sequencing reads were generated from
54 of 55 asthma patients. The paired end reads were rarefied to 9311 reads resulting in one
patient sample being excluded due to low reads (4693 reads). Sequences were clustered into
167 OTUs. The OTUs Streptococcus spp. and Prevotella spp. were detected in all patients with
high mean abundance (%) (Table 3 and Fig 1). Despite the large number of OTUs identified
from this cohort, only 11 OTUs were found in�90% of the patients. These includedH. parain-
fluenzae, which was found in 90.7% patients. Based on a previous classification [25], OTUs
were divided into aerobes/anaerobes (Table 3). Among the most prevalent OTUs, 27% were
identified as aerobes, with Streptococcus spp. the most common. Among other OTUs found
from this cohort were the generaMoraxella, Pseudomonas and Staphylococcus. ThoughMorax-
ella spp. accounted for only 33% of the cohort, 4 patients (aged 68–71 years) had a very high
relative abundance of the genus (16.17–52.59%). S. aureus was identified in 61% of patients;
only one patient had this taxon as a high relative abundance (17.65%) with others below 4%.
Pseudomonas spp. was found in 81% of the cohort, with all relative abundances below 4%.
Correlation of lung microbiota with ICS dose. ICS dose (high or low) did not affect spe-
cies richness (p = 0.23), diversity (Simpson’s Diversity Index, p = 0.134), or community struc-
ture (Shannon’s index, p = 0.256). The microbiota composition in patients from the low- and
high-dose ICS groups is shown in Fig 2. No significant differences were observed in the micro-
biota composition between the groups (Bray-Curtis; p = 0.676).
Table 2. Frequency distribution of patient groups attending visit 1 and visits 2 and 3 based on treatment group.
Treatment group ICS Visit 1 (n =) Visit 2 (24 h) and 3 (2 weeks) (n =)
Low-dose ICS (n = 22) BDP (�400 μg/day) 10 6
BUD (�400 μg/day) 7 2
FP (�200 μg/day) 5 0
High-dose ICS (n = 33) BUD (�800 μg/day) 16 4
FP (�500 μg/day) 17 7
Total 55 19
BDP: Beclomethasone dipropionate; BUD: Budesonide; FP: Fluticasone propionate; ICS: inhaled corticosteroid.
https://doi.org/10.1371/journal.pone.0244681.t002
Table 3. The most prevalent OTUs across samples (90–100% patients) in descending order of mean abundance (%).
OTU Mean abundance (%) Relative abundance ranges (%) Oxygen requirements
Streptococcus spp. 14.13 0.01–45.85 Aerobe
Veillonella dispar 4.60 0.003–30.33 Anaerobe
Prevotella spp. 4.02 0.003–33.82 Anaerobe
Fusobacterium spp. 3.73 0.009–34.69 Anaerobe
Oxalobacteriaceae 3.58 0.001–72.44 Both
Haemophilus parainfluenzae 2.58 0.001–24.49 Aerobe
Mogibacterium spp. 1.43 0.001–18.85 Aerobe
Lachnospiraceae 1.03 0.001–10.16 Anaerobe
Atopobium spp. 0.77 0.002–12.21 Anaerobe
Selenomonas spp. 0.63 0.001–9.26 Anaerobe
Prevotella pallens 0.45 0.001–4.87 Anaerobe
https://doi.org/10.1371/journal.pone.0244681.t003
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Load changes of individual OTUs between ICS dose groups are presented in Table 4. In
total, 32 OTUs were significantly more prevalent in low-dose ICS patients. Among these were
5 of the most prevalent OTUs from the cohort as a whole (Streptococcus spp., V. dispar, Atopo-
bium spp., Selenomonas spp. and P. pallens; Table 3). Streptococcus spp. was the most abundant
OTU detected in the low-dose ICS group (2.6 x 107 CFU/ml), at significantly higher levels
than were found in the high-dose ICS group (1.72 x 106 CFU/ml, p = 0.002). Three other mem-
bers of the Prevotella genus (besides P. pallens) were also found to be more abundant in the
low-dose ICS group, namely P. tannerae, P. melaninogenica and P. nigrescens (Table 4). Most
of the more abundant organisms in low-dose ICS patients were anaerobes. Only 7 OTUs were
significantly higher in high-dose ICS patients but with lower mean abundances than those
more frequent in the low-dose group (Dysgonomonas spp., Parvimonas spp.).
Fig 1. Top 20 OTUs identified from 54 patients, with the highest mean abundance (%) being the topmost. The
colours indicate the abundance of OTUs in each patient, with blue regarded as low abundance, red as moderate
abundance and green as high abundance.
https://doi.org/10.1371/journal.pone.0244681.g001
Fig 2. The Non-metric Multidimensional Scaling (NMDS) plot represented the bacterial composition of each
patient, grouped by ICS dose; low-dose ICS (red) and high-dose ICS (blue). The shorter the distance between the
dots, the more similar the bacterial compositions were between the patients.
https://doi.org/10.1371/journal.pone.0244681.g002
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Correlating lung microbiome with type of high-dose ICS. Species richness was not sig-
nificantly different between high-dose FP and BUD treated subjects (p = 0.9). Similarly, non-
Table 4. Significant OTU changes between ICS dose groups.
OTU Low-dose ICS High-dose ICS p-value
Mean (CFU/ml)� Mean (CFU/ml)�
Acidocella spp. 3.77E+04 " 3.29E+03 0.011
Actinomyces spp. 2.40E+06 " 1.78E+05 0.02
Aggregatibacter segnis 4.06E+05 " 2.35E+04 0.043
Atopobium spp. 6.14E+05 " 8.16E+04 0.006
Bacillaceae 1 2.27E+04 2.62E+05 " 0.047
Bacillaceae 2 1.73E+04 1.82E+05 " 0.031
Campylobacter spp. 7.13E+05 " 2.26E+05 0.048
Capnocytophaga spp. 4.09E+05 " 1.28E+04 0.005
Cardiobacterium spp. 3.00E+04 " 6.50E+02 0.019
Catonella spp. 1.46E+05 " 2.56E+04 0.048
Cerasicoccaceae 0.00E+00 4.81E+04 " 0.045
Corynebacterium durum 2.51E+04 " 6.90E+03 0.031
Dialister spp. 7.35E+05 " 1.39E+05 0.016
Dysgonomonas spp. 5.72E+02 5.32E+04 " 0.008
Enterobacteriaceae 1.89E+01 6.52E+03 " 0.032
Granulicatella spp. 1.23E+06 " 6.41E+04 0.015
Lautropia spp. 7.41E+05 " 2.09E+04 0.039
Leptotrichia spp. 1.08E+07 " 2.19E+06 0.003
Megasphaera spp. 3.83E+05 " 5.73E+04 0.009
Microbacteriaceae 8.97E+05 9.13E+05 " 0.012
Moryella spp. 8.02E+05 " 6.00E+04 0.001
Neisseriaceae 2.42E+05 " 5.25E+03 0.007
Oribacterium spp. 7.87E+05 " 1.60E+05 0.006
Parvimonas spp. 5.02E+05 7.60E+06 " 0.005
Prevotella melaninogenica 1.07E+07 " 1.57E+06 0.016
Prevotella nigrescens 1.53E+05 " 4.77E+03 0.008
Prevotella pallens 7.37E+05 " 1.77E+05 0.029
Prevotella tannerae 5.67E+05 " 3.72E+04 0.031
Rothia aeria 6.17E+05 " 1.99E+04 0.005
Rothia dentocariosa 8.44E+05 " 6.31E+04 0.01
Rothia mucilaginosa 1.40E+07 " 6.09E+05 0.021
Selenomonas noxia 2.91E+04 " 5.21E+02 0.028
Selenomonas spp. 6.82E+05 " 3.10E+05 0.006
Streptococcus anginosus 9.52E+04 " 1.17E+04 0.002
Streptococcus spp. 2.60E+07 " 1.72E+06 0.002
TM_7.Rs_045 1.38E+05 " 1.34E+03 0.035
TM7 5.68E+05 " 1.44E+04 0.002
Veillonella dispar 8.80E+06 " 1.09E+06 0.013
Weeksellaceae 5.80E+04 " 4.62E+03 0.002
Group with highest comparative abundance of each OTU signified by ".
� normalised OTU relative abundance (%) were multiplied by their corresponding qPCR-derived total bacterial load
obtained from the qPCR data to give a CFU/ml value.
https://doi.org/10.1371/journal.pone.0244681.t004
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significant values were evident for Simpson’s Diversity Index (p = 0.787) and community
structure (p = 0.887). The microbiota composition in patients from different types of high-
dose ICS groups is shown in Fig 3. The Bray-Curtis distances between groups showed no sig-
nificant differences in bacterial composition (p = 0.345).
Haemophilus and high-dose ICS. A total of 9 OTUs had significantly higher mean abun-
dance in the high-dose FP group (Table 5). Among these, H. parainfluenzae had a significantly
higher abundance in individuals taking high-dose FP (mean abundance: 9.64 x 105 CFU/ml)
than those taking high-dose BUD (1.45 x 105 CFU/ml, p = 0.047). This led to the qPCR investi-
gation to determine H. influenzae and S. pneumoniae loads in high-dose FP and BUD groups
(described in S1 File and S1 Fig), which determined H. influenzae loads were significantly
higher than S. pneumoniae in both high-dose FP and BUD groups but found no significant dif-
ferences in H. influenzae or S. pneumoniae loads between these groups.
Changes in microbiota over time. Both analyses on microbiota composition and qPCR
total bacteria data between different time points (Day 1, 2 and 14) of 19 patients demonstrated
no significant changes in diversity measures and bacterial load (Fig 4). The overall composi-
tion was measured by species richness, diversity (Simpson’s) and community structure (Shan-
non’s) with no significant changes between different time points.
Discussion
This study presents a culture-independent analysis of bacteria present in respiratory samples of
adults with clinically stable asthma and provides several important and novel findings to the field
of asthma microbiome studies. All individuals had been taking the same type and dose of ICS for
at least a year allowing the impact of long-term usage to be evaluated. A number of patients were
sampled more than once allowing insights into short-term asthma microbiota stability.
Fig 3. The Non-metric Multidimensional Scaling (NMDS) plot based on bacterial composition of patients on
high-dose ICS taking budesonide (red) and fluticasone propionate (blue). The shorter the distance between the
dots, the more similar the bacterial compositions were between the patients.
https://doi.org/10.1371/journal.pone.0244681.g003
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From the 167 OTUs identified, a restricted number (eleven) were found in over 90% of
individuals studied. This is in keeping with findings for the cystic fibrosis airways microbiome
in which core and transient populations have been established [25]. In this study, the taxa
identified often matched those previously found in asthma and in cystic fibrosis and bronchi-
ectasis such as Streptococcus spp., Haemophilus spp. and anaerobes (Veillonella spp., Prevotella
spp.). These have been detected in poorly-controlled asthma in adults [16, 26], treatment-resis-
tant severe asthma in adults [14] and mild [27] and severe asthma patients [10]. Of these gen-
era, Haemophilus and Streptococcus include species considered in other contexts to be
pathogens. The consequence of identifying putative pathogens in the asthmatic airways raises
important clinical questions as to their potential contribution to the pathophysiology of
asthma and also whether or not to treat potential pathogens when detected by such
Fig 4. The NMDS (non-metric multidimensional scaling) of the microbiota composition of asthma patients (top) and
total bacterial load (log CFU/ml +1) (bottom) grouped into ICS dose group of low-dose ICS (red) and high-dose ICS
(green) at (a) Day 1, (b) Day 2 (after 24 h) and (c) Day 14 (after 2 weeks).
https://doi.org/10.1371/journal.pone.0244681.g004
Table 5. OTU changes between type of ICS in the high-dose ICS group.
OTU FP (n = 17) BUD (n = 16) p-value
Mean (CFU/ml) Mean (CFU/ml)
Anaerobacillus spp. 1.00E+05 " 8.26E+04 0.026
Capnocytophaga ochracea 1.07E+04 " 1.22E+03 0.038
Dysgonomonas spp. 5.33E+04 " 5.31E+04 0.035
Exiguobacterium spp. 3.12E+02 4.43E+03 0.026
Fluviicola spp. 1.38E+01 1.26E+03 0.043
Haemophilus parainfluenzae 9.64E+05 " 1.45E+05 0.047
Lactobacillus reuteri 2.85E+04 " 0.00E+00 0.027
Paracoccus spp. 9.00E+04 1.95E+05 0.016
Peptococcus spp. 1.86E+04 " 6.93E+01 0.014
Porphyromonas endodontalis 6.40E+04 " 6.01E+03 0.009
Rhodobaca spp. 1.80E+04 1.90E+04 0.049
Veillonellaceae 1.18E+04 " 5.81E+00 0.048
Xanthomonadaceae 7.18E+04 " 5.31E+03 0.019
BUD: Budesonide; FP: Fluticasone propionate, ICS: inhaled corticosteroid.
" higher in FP compared to BUD.
https://doi.org/10.1371/journal.pone.0244681.t005
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technologies. In relation to this, it is important to consider the bacterial load carried in the
asthmatic airways. The average sputum bacterial load of this cohort (~1x107 CFU/mL) is
between that observed in healthy controls (<1x106 CFU/mL) [28] and in cystic fibrosis
(~1x108 CFU/mL) [29]. As such, the potential for pathophysiological airway damage is a dis-
tinct possibility in asthmatic individuals.
The relationship between ICS dose and lung microbiota composition was explored. The
clinical characteristics of the low- and high-dose ICS groups were similar with no significant
differences in FEV1, FENO or peak blood eosinophil count/number of severe asthma exacerba-
tions in the last year. In general, ICS dose did not affect ecological community characteristics.
In contrast, previously, microbiota from severe asthmatics (taking a similar dose of ICS to our
high-dose group) was enriched in 53 genera compared to mild/moderate subjects, the majority
being Actinobacteria, with the remaining 5 classifying to Gammaproteobacteria [30]. The dif-
ferences between previous results and our findings may be due in part by fact that Huang et al.
sampled the microbiota via bronchial brushings. It is also possible that the severe asthma
group from this study had sub-optimal asthma control whilst our high-dose ICS group were
generally well-controlled.
A number of genera had significantly higher relative abundances in low-dose ICS patient
samples with a smaller number of OTUs detected that were more abundant in the high-dose
group. The most prevalent OTU identified in low-dose samples was Streptococcus spp. This
genus contains species that differ in their potential to cause pathophysiological damage and
without extensive subsequent analysis it is not possible to assess whether the Streptococcal spe-
cies being detected are pathogens or not. Cox et al. [31] previously reported that 16S rRNA
gene sequencing was unable to discriminate between S. pneumoniae and Streptococcus mitis, the
latter being a normal commensal of the oropharynx. A smaller set of genera were more abun-
dant in the high-dose ICS group. Of these, the most prevalent was Parvimonas spp. a genus that
contains species regarded as human pathogens [32]. The significance of the differing abun-
dances of these genera between high- and low-dose ICS groups is however unclear. These differ-
ences may be part of a process which is either a cause or consequence of disease progression. It
is also possible that ICS act as “selecting agents” for certain species. In many studies high doses
of specific compounds are associated with selection of a few distinct taxa [33].
No significant differences in overall microbiota composition or bacterial load were identi-
fied between patients taking high-dose BUD and high-dose FP. However a higher abundance
of H. parainfluenzae was identified in the high-dose FP group than in those using high-dose
BUD. A selective effect of long-term FP usage on the abundance of this potential pathogen is
therefore a possibility. Goleva et al. [34] found an increased abundance of H. parainfluenzae in
asthmatics “resistant” to a treatment trial of oral prednisolone in comparison to those who
were steroid “sensitive” and an inhibitory effect of H. parainfluenzae on asthmatic airway mac-
rophages in vitro was also observed. The differences in abundance of other organisms between
high-dose BUD and FP are of uncertain significance and include some organisms usually asso-
ciated with oral (Veillonellaceae, Porphyromonas endodontalis) and GI (Lactobacillus reuteri,
Peptococcus spp.) microbiota.
Evidence is accumulating that ICS treatment is associated with an increased risk of pneu-
monia in COPD [6, 35] and respiratory infection in asthma [4, 5] and that this increased risk
is greater with FP [36] than BUD. Our findings, combined with the observation that short-
term treatment with FP can cause distinct changes in the microbiota [37], provide a possible
mechanism but a prospective study of the microbiota of patients starting different ICS is really
required to strengthen these observations.
This study also examined the short-term stability of the asthma microbiota. No statistically
significant differences were seen in community composition between the three time points
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over two weeks, suggesting the asthma microbiome is typically stable over short periods of
time in clinical stability.
This study has limitations. Microbial contamination, possible from the oral cavity, has been
covered extensively elsewhere [38]. No evidence for gross contamination was observed here
with the commonality of species detected across over 90% of individuals with asthma support-
ive of non-contaminated sample collection. A further limitation could be considered the lack
of subject phenotyping. Distinct asthma phenotypes may have distinct airways microbiota
[39]. This will need to be considered when designing future studies. Also, the mean age of our
patients was higher than previous studies [10, 27, 30]. Whilst the effect of age on the micro-
biota has not previously been investigated, data from CF patients suggest a decrease in micro-
biota diversity with age [40]. Finally, a “molecular” limitation was that the differences in taxa
were described primarily at genus level making the biological effects less clear.
Conclusions
This study did not demonstrate a significant difference in microbiota composition between
asthma patients taking low- and high-dose ICS. However, an association was identified
between high-dose FP and increased abundance of the pathogen H. parainfluenzae. The clini-
cal implications for patients are not known but this does provide a possible explanation for the
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